Over the next five years the Anti-tumor Drug market will register a 7.40% CAGR in terms of 256.66 billion, the global market size will reach USD 256.66 billion by 2029.
Anti-tumor Drug Market Overview
Cancer immunotherapy is a sort of therapy that supports the immune system's battle against the disease. Breast and prostate cancers that utilize hormones to grow can be treated with hormone therapy to delay or stop their growth. The anticancer medications are less selective for cancer cells and prevent cell division and proliferation.
Therefore, these medications kill both cancerous and healthy cells. Chemotherapy and anticancer medications can stop the growth of cancer cells, thereby deactivating them. Anticancer medications slow the division of cancer cells, but normal cells are also impacted by the process.
The rise in incidence and prevalence of different cancer disorders, the popularity of advanced therapies (such as biological and targeted pharmacological therapies), and the rising global elderly population are the main factors driving the expansion of the anti-tumor drug market. Additionally, the market for anti-tumor drugs is growing as a result of increased cancer awareness and early cancer detection.
What is our Anti-tumor Drug Market report scope?
|
Report Attributes
|
Report Details
|
|
Forecast Period 2022 to 2029 CAGR
|
CAGR of 7.40% during the review period (2022 to 2029).
|
|
By Drug
|
- Cytotoxics
- Hormonal Therapy
- Targeted Therapy
- Others
|
|
By End Users
|
- Hospitals
- Homecare
- Specialty Clinics
- Others
|
|
By Companies
|
Amgen Inc., Astellas Pharma Inc., AstraZeneca plc, Bayer AG, Biogen Inc., Bristol-Myers Squibb, Celgene Corporation, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, Johnson & Johnson, Merck & Co., Inc. and Others.
|
|
Regions Covered
|
- North America
- Europe
- Asia-Pacific
- Rest of the World
|
|
Countries Covered
|
- US
- Canada
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East & Africa
- Latin America
|
|
Base Year
|
2021
|
|
Historical Year
|
2017 to 2021
|
|
Forecast Year
|
2022 to 2029
|
|
Number of Pages
|
135
|
|
Customization Available
|
Yes, the report can be customized as per your needs
|
Frequently Asked Questions
What is the study period of this market?
The Anti-tumor Drug Market is studied from 2022 - 2029.
What is the growth rate of Anti-tumor Drug Market?
The Anti-tumor Drug Market is growing at a CAGR of 7.40% over the next 7 years.
Who are the key players in Anti-tumor Drug Market?
Amgen Inc., Astellas Pharma Inc., AstraZeneca plc, Bayer AG, Biogen Inc., Bristol-Myers Squibb, Celgene Corporation, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, Johnson & Johnson, Merck & Co., Inc. and Others.
What region does this Anti-tumor Drug Market report covers?
North America (the United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, and Italy)
Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)
South America (Brazil, Argentina, Colombia, etc.)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)
What are the Drug types of Anti-tumor Drug Market?
Cytotoxics, Hormonal Therapy, Targeted Therapy and Others.
What are the End - User in Anti-tumor Drug Market?
Hospitals. Homecare, Specialty Clinics and Others
The following companies are major players in the Anti-tumor Drug market:
The Anti-tumor Drug market is rapidly expanding, with numerous local and regional vendors focusing on specific application goods for a wide range of end users. The three criteria for the market standing of big corporations are: corporate profile, profitable gross margin, and pricing charged. These are the players that are dominating the global market: Amgen Inc., Astellas Pharma Inc., AstraZeneca plc, Bayer AG, Biogen Inc., Bristol-Myers Squibb, Celgene Corporation, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, Johnson & Johnson, Merck & Co., Inc. and Others
Industry News:
In April 2022 - Based on DESTINY-Breast04 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a significant improvement in both progression-free survival and overall survival, Enhertu has now been granted five Breakthrough Therapy Designations, including three in breast cancer and one in both lung and gastric cancers
What are the major Applications, Types and Regions for Anti-tumor Drug Market?
By Drug, it is segmented into
- Cytotoxics
- Hormonal Therapy
- Targeted Therapy
- Others
By End-User, it is segmented into
- Hospitals
- Homecare
- Specialty Clinics
- Others
Anti-tumor Drug Market Regional Analysis
North America dominates the global market for mouth ulcer therapy due to technological In terms of market 256.66 billion and market share, North America now controls the proctitis market and will maintain this position of strength throughout the projection period. This occurs as a result of the existence of significant important actors, the region's well-developed healthcare infrastructure, an increase in proctitis incidence, and kind reimbursement policies.
On the other hand, Asia-Pacific is anticipated to see the fastest growth rate throughout the projection period as a result of rising government backing and increased awareness of proctitis in developing nations.
The market for Anti-tumor Drug in Asia is predicted to increase rapidly over the next few years, followed by Europe. In Asia, China and India are likely to be the fastest expanding markets.
- North America
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Rest of the World
- Middle East & Africa
- Latin America
The Anti-tumor Drug Market describes the factors driving the global growth opportunities in upcoming years and highlights market channels. In addition, the report analyzes market size and share, trends, by geographic region, end-use type and segment. It focuses extensively on revealing a detailed regional analysis. The Global Anti-tumor Drug Market report also conducted a PESTEL analysis of the industry to study the main influencing factors and entry barriers of the industry.
SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.
PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.
MARKET ENGINEERING
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.
EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.
REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.
